Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Opinion|Videos|February 14, 2025 (Updated: January 31, 2025)
Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
This segment examines the evidence supporting cilta-cel in second-line therapy, highlighting key outcomes from the CARTITUDE trials and comparing them to other available second-line treatment options for multiple myeloma.
Advertisement
Video content above is prompted by the following:
- Please discuss the evidence supporting cilta-cel in second-line therapy.
- Which key outcomes from the CARTITUDE trials guide your decision to choose cilta-cel in the second-line setting?
- How do these findings compare with other available second-line treatments for multiple myeloma in this patient group?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
3
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
4
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
5